Allozyne

United States
Seattle, Washington, United States, 98102

Company profile

Allozyne company profile

Allozyne develops and commercializes technologies that enable improvements in the efficacy, safety, dosing, and other characteristics of protein-based therapeutics, including peptides, antibodies, and vaccines. Its PEGylated IFN beta is for the treatment of multiple sclerosis. The company was founded in 2005 and is based in Seattle, Washington.

Business identity

Contact email
[email protected]
Phone number
206-518-5700
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2005-01-01, Year

Headquarters

Postal code
98102
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
4
Total equity funding
$33.5M
Last funding
Debt Financing / $900,000 / 2013-04-05
Last equity funding
Series B / $30M
Investors
5
Lead investors
1
Founders
3
Articles
19
Exited on
2014-09-19

Founders and investors

Founders

David A. TirrellDee DattaWilliam A. Goddard

Lead investors

MPM Capital

Investors

Alexandria Real Estate EquitiesAmgen VenturesARCH Venture PartnersMPM CapitalOVP Venture Partners